




PRESS RELEASE

SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors



Collaboration combines SEngine's PARIS[®] Test platform for drug screening on live patient-derived tumor cells and Oncodesign's Nanocyclix[®] technology for generation of novel kinase inhibitors

Seattle (US) and Dijon (France), February 08, 2022 at 06:00 pm CET - <u>SEngine Precision Medicine Inc.</u>, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, and <u>Oncodesign</u> (ALONC – FR0011766229), a French biopharmaceutical company specialized in precision medicine, have announced the signature of a research collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

SEngine is commercializing the PARIS[®] Test, a leading-edge diagnostic tool that pre-screens a broad panel of marketed cancer drugs on live patient-derived tumor cells. The results are analyzed using proprietary algorithms, culminating in a clinically actionable drug sensitivity report provided to oncologists for patients whose cancer has no remaining actionable treatment protocols. <u>Dramatic results</u> on the test's predictive value have been reported for a number of terminally ill cancer patients.

Oncodesign has developed Nanocyclix[®], a medicinal chemistry platform for generating highly potent and selective small macrocyclic kinase inhibitors. Using a probe-based drug discovery paradigm aimed to find highly effective inhibitors for intractable kinases, Oncodesign has built an extensive set of high potential compound probes that are highly novel. Since its inception, Oncodesign has advanced a two of these compounds to near clinical stage.

Testing of a subset of potent and selective Nanocyclix[®] probes against an undisclosed target proposed by SEngine has shown significant selective cancer cell killing effects on a broad range of patient-derived live 3D-tumor cell systems (organoids) for multiple cancer types that are highly aggressive and without currently existing treatment options. This observation confirms the potential use of the Nanocyclix[®] probes in SEngine's precision oncology platform to transform future cancer treatments.

SEngine and Oncodesign have initiated a joint research collaboration to evaluate the feasibility to convert the already identified Nanocyclix[®] inhibitor series into drug candidates that are likely to be effective in the clinic. During this initial phase, both companies will combine their respective technology platforms to advance the program. SEngine will provide research funding to Oncodesign for the initial optimization of the compound series up to a predefined level. It is anticipated that this initial phase will be followed by a larger research collaboration with an option to license at a more advanced stage.





Carla Grandori, MD, PhD, CEO and co-founder of SEngine, stated: *"I am thrilled to expand our collaboration with* Oncodesign, now that their candidate kinase inhibitors have shown efficacy against a panel of patient-derived organoids for specific solid tumors. It is a new era for drug development, where drugs are pre-tested on minicancers grown in 3D shortly after ex vivo derivation, a significant improvement over the historical use of established *cell-line models. SEngine's PARIS® Test is highly predictive of in vivo drug response and allows us to bring novel therapeutics towards clinical evaluation with higher chances of success."*

Philippe Genne, CEO and founder of Oncodesign, said: *"This collaboration with SEngine goes right to the heart of our company's mission: finding novel treatments for cancer patients that have no remaining solutions. We already are working on target identification with Oncosnipe® and our IA Business Unit and partnering with SEngine widens our horizon as the combination of Nanocyclix® and the PARIS® Test, two important technologies for personalized cancer treatment discovery, opens the door for a highly innovative way of discovering effective new cancer treatments, starting from biological material directly derived from patients."*

Jan Hoflack, CSO of Oncodesign, added: "The results already obtained with our Nanocyclix[®] probes in patient derived live cellular cancer organoids has generated high enthusiasm at both Oncodesign and SEngine. Combining our forces has the potential to dramatically change lives of patients with advanced, metastatic and uncurable cancers of multiple types and origin. Our teams have already started working to come to clinical candidate molecules."

About PARIS® Test

The PARIS® Test is a next generation diagnostic test that predicts drug responses by pre-screening a broad panel of cancer drugs in patient-derived live tumor cells using robotics and Al-driven computational tools. SEngine's CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Cancer derived cells grown in 3D outside the body maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS® Test provides crucial information to treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine

SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with phenotypic testing of patient-derived live cells combined with robotics and AI-driven computational tools. SEngine's CLIA¹ certified PARIS® Test generates actionable drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharmaceutical companies by deploying its precision oncology platform.

¹ Clinical Laboratory Improvement Amendments





PRESS RELEASE

About Oncodesign: www.oncodesign.com

Oncodesign is a biopharmaceutical company specializing in precision medicine, founded in 1995 by its current CEO and majority shareholder. It has been listed on the Euronext Growth Market since April 2014. Its mission is to discover effective therapies to fight cancer and other diseases without a therapeutic solution. With its unique experience, enriched thanks to over 1.000 customers - including the world's largest pharmaceutical companies - and based on a oneof-a-kind technological platform combining artificial intelligence, medicinal chemistry, pharmacology, regulatory bioanalysis and cutting-edge medical imaging, Oncodesign is able to select new therapeutic targets, then design and develop potential preclinical candidates up to the clinical phase stage. Oncodesign has configured its organization to offer innovative services to its customers and licenses for its proprietary molecules. When applied to kinase inhibitors – molecules that represent a market estimated to be worth more than \$65 billion by 2027 and nearly 25% of R&D investments in the pharmaceutical industry - Oncodesign's technology has already made it possible to target several molecules of interest with a high therapeutic potential, both in and outside of oncology, and has signed partnerships with international pharmaceutical groups. Based in Dijon, France, at the heart of the University Hospital complex as well as the Paris-Saclay complex, Oncodesign boasts 230 employees across three Business Units (BU) - Service, Biotech, and Artificial Intelligence – and has subsidiaries in Canada and the United States.

Contacts

SEngine

Renee Volpini Media Relations Tel.: 917-923-8117 reneevolpini@aol.com

Oncodesign

Philippe Genne Chairman and CEO Tél. : +33 (0)380 788 260 investisseurs@oncodesign.com

NewCap

Mathilde Bohin Investor Relations Tél. : +33 (0)144 719 495 oncodesign@newcap.eu



NewCap

Arthur Rouillé Media Relations Tél. : +33 (0)144 710 015 oncodesign@newcap.eu

Forward-looking statements

This document contains forward-looking statements and estimates regarding the financial position, results of operations, strategy, projects and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates may be recognized by the use of words such as, without limitation, "believe", "anticipate", "predict", "expect", "project", "plan", " intend", "estimate", "may", "expect "want", "continue" and similar expressions. These include all questions that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors that were considered reasonable when made but may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the control of the Company. Accordingly, the Company's actual results, financial conditions, performance or achievements, or industry results, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. In light of these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates are only valid as of the date of publication of this document.

The Company disclaims any obligation to update such forwardlooking statements, forecasts or estimates to reflect any change in the Company's expectations relating thereto, or any change in the events, conditions or circumstances on which such statements, forecasts or estimates are based, except as required by French law.